CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 75-95% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Liquidia Q3 loss widens on litigation charge, negating Yutrepia demand

By Reuters News


Overview

  • U.S. biopharma firm's Q3 revenue surged year-over-year, driven by YUTREPIA sales growth

  • Company posted large net loss due to $389.7 mln litigation settlement charge

  • Company said patient shipments of YUTREPIA reached record monthly levels in October


Outlook

  • Company expects LTI-403 study in PAH patients switching from oral selexipag to complete in 2Q2027

  • SPRINT trial evaluating YUTREPIA in PAH expected to begin in 4Q2026

  • L606 Re-Spire study in PH-ILD expected to complete enrollment in 2028 and primary study in 2029


Result Drivers

  • YUTREPIA SALES VOLUME - Co attributed revenue growth to higher sales volume of YUTREPIA inhalation powder

  • PRESCRIBER GROWTH - Co reported increase in prescriber base and more first-time prescribers for YUTREPIA


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Total Revenue

$225.30 mln

Q3 EPS

-$2.64

Q3 Net Loss

$236.33 mln

Q3 Operating Income

-$263.52 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the pharmaceuticals peer group is "buy"

  • Wall Street's median 12-month price target for Liquidia Corporation is $58.00, about 21.2% above its November 9 closing price of $47.87

  • The stock recently traded at 23 times the next 12-month earnings vs. a P/E of 18 three months ago


Reuters Recommended Reads

  • Nov 9 - Biopharma Almirall 9M sales rise on European dermatology growth

  • Nov 9 - TG Therapeutics Q3 product revenue rises on BRIUMVI sales; lifts 2026 outlook

  • Nov 9 - ImmunityBio Q3 revenue rises on Anktiva sales growth but misses estimates


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.